Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin

Jingru Meng,1,5 Xue Ma,1,5 Ning Wang,1,5 Min Jia,1 Long Bi,2 Yunying Wang,3 Mingkai Li,1 Huinan Zhang,1 Xiaoyan Xue,1 Zheng Hou,1 Ying Zhou,1 Zhibin Yu,3 Gonghao He,4,6 and Xiaoxing Luo1,*

1Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi’an 710032, China
2Institute of Orthopaedics & Traumatology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China
3Department of Aerospace Physiology, Fourth Military Medical University, Xi’an 710032, China
4Department of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming 650032, China
5Co-first author
6Co-senior author
*Correspondence: xxluo3@fmmu.edu.cn

http://dx.doi.org/10.1016/j.stemcr.2016.02.002
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

SUMMARY

Glucagon-like peptide 1 (GLP-1) plays an important role in regulating bone remodeling, and GLP-1 receptor agonist shows a positive relationship with osteoblast activity. However, GLP-1 receptor is not found in osteoblast, and the mechanism of GLP-1 receptor agonist on regulating bone remodeling is unclear. Here, we show that the GLP-1 receptor agonist exendin-4 (Ex-4) promoted bone formation and increased bone mass and quality in a rat unloading-induced bone loss model. These functions were accompanied by an increase in osteoblast number and serum bone formation markers, while the adipocyte number was decreased. Furthermore, GLP-1 receptor was detected in bone marrow stromal cells (BMSCs), but not in osteoblast. Activation of GLP-1 receptor by Ex-4 promoted the osteogenic differentiation and inhibited BMSC adipogenic differentiation through regulating PKA/β-catenin and PKA/PI3K/AKT/GSK3β signaling. These findings reveal that GLP-1 receptor regulates BMSC osteogenic differentiation and provide a molecular basis for therapeutic potential of GLP-1 against osteoporosis.

INTRODUCTION

Osteoporosis is the most common metabolic bone disease, and it affects many people such as the elderly, long-term bed-ridden patients, astronauts, and persons living sedentary lifestyles (Armbrecht et al., 2011; Edwards et al., 2015; Lau and Guo, 2011; Rachner et al., 2011). Disuse or unloading-induced osteoporosis leads to an insufficient number of osteoblasts or a reduction in their function. These effects are well known as some of the main causes in the pathogenesis of osteoporosis (Kondo et al., 2011; Nakamura et al., 2013). Therefore, drugs that induce the differentiation and proliferation of osteoblasts, thus promoting bone formation, may represent a strategy for the prevention and treatment of osteoporosis, which, however, still remains an unmet medical need.

Recent reports showed that glucagon-like peptide-1 (GLP-1), a gastrointestinal hormone whose release is stimulated by ingestion, acts as an important modulator of bone growth and remodeling (Kim et al., 2013; Yamada et al., 2015; Lau and Guo, 2011; Rachner et al., 2011). Disuse or unloading-induced osteoporosis leads to an insufficient number of osteoblasts or a reduction in their function. These effects are well known as some of the main causes in the pathogenesis of osteoporosis (Kondo et al., 2011; Nakamura et al., 2013). Therefore, drugs that induce the differentiation and proliferation of osteoblasts, thus promoting bone formation, may represent a strategy for the prevention and treatment of osteoporosis, which, however, still remains an unmet medical need.

GLP-1 and its analogs have been shown to have a number of physiological and pharmacological effects, including the promotion of bone formation and remodeling (Kim et al., 2013; Yamada et al., 2015; Lau and Guo, 2011; Rachner et al., 2011). In our previous investigation, we suggested that exendin-4 (Ex-4), a peptide analog of GLP-1, could induce bone formation by osteoblast activation in old ovariectomized (OVX) rats (Ma et al., 2013), raising a new question regarding the downstream molecular mechanisms underlying the osteogenic effect. The elucidation of this effect would provide insight into the pathophysiology of osteoporosis and the pharmacological properties of GLP-1 and its analogs.

GLP-1 and its analogs exert their physiological and pharmacological effects mainly via the GLP-1 receptor (GLP-1R). However, at present GLP-1R expression in osteoblasts has not been clearly confirmed. Many studies reported that GLP-1R was not expressed in primary osteoblasts and Saos-2 cells (Aoyama et al., 2014; Bollag et al., 2000; Yamada et al., 2008). Other research reported that GLP-1R was expressed in young osteoblasts derived from TE-85 and MG-63, but not in mature osteoblasts derived from Saos-2 osteosarcoma cell line (Pacheco-Pantoja et al., 2011). At the same time, GLP-1R was also detected during osteogenic differentiation of human adipose-derived stem cells (Jeon et al., 2014). In our previous work, we found that Ex-4 osteogenic action in OVX rats was a consequence of the differentiation of bone marrow stromal cells (BMSCs) through the promotion of osteogenesis and a simultaneous suppression of adipogenesis (Ma et al., 2013). Moreover, additional experimental analyses demonstrate the presence of the GLP-1R mRNA and protein in human BMSCs (Sanz et al., 2010). These lines of evidence provide a strong hint that BMSCs might be a cell target that mediates the osteogenic effect of GLP-1 and its analogs.

BMSCs are potential stem cells with the ability to differentiate into osteoblasts or adipocytes depending on the situation (Pittenger et al., 1999). Indeed, several molecules...
osteoporosis.

GLP-1 and its analogs as rather promising drugs against osteogenic potential through the regulation of the PKA/β-catenin signaling in tail-suspended rats, our results showed that GLP-1Rs are G-protein-coupled receptors able to induce intracellular cAMP formation and trigger the cAMP-protein kinase A (PKA) signaling pathway when activated (Hayes et al., 2011; Holst, 2007). The enhancement of cAMP signaling was reported to facilitate β-catenin signaling in many types of cells (Jiang et al., 2013; Liu and Habener, 2008; Zhang et al., 2014). Therefore, since GLP-1Rs are G-protein-coupled receptors able to induce intracellular cAMP formation and trigger the cAMP-protein kinase A (PKA) signaling pathway when activated (Hayes et al., 2011; Holst, 2007), we hypothesized that Ex-4 might exert its osteoblast activation effect by inducing cAMP and β-catenin signaling in BMSCs.

To prove our hypothesis, we investigated the effect of Ex-4 on BMSC differentiation and bone formation both in vitro and in vivo. With the induction of disuse osteoporosis in tail-suspended rats, our results showed that GLP-1R activation improved osteoporosis and promoted BMSC osteogenic potential through the regulation of the PKA/β-catenin signaling pathway. These results advocate GLP-1 and its analogs as rather promising drugs against osteoporosis.

RESULTS

GLP-1R Agonist Ex-4 Increased Bone Mass and Bone Strength in Hindlimb-Unloading-Induced Bone Loss Rats

To elucidate the role of GLP-1R in the control of skeletal homeostasis, we analyzed the bone structural characteristics after GLP-1R agonist Ex-4 treatment in hindlimb-unloading rats. After mechanical unloading for 4 weeks, hindlimb-unloading rats exhibited a lower bone mineral density (BMD) and fewer, thinner, and more broken trabecular bones in femur and vertebra compared with the rats in the normal control group not subjected to hindlimb unloading as well as any other treatment, as displayed by the microcomputed tomography (microCT) scans of femur and vertebra. However, the trabecular architecture was remarkably improved in the Ex-4-treated rats belonging to the hindlimb-unloading treatment group compared with the rats in the hindlimb-unloading control group treated with the vehicle. The BMD and bone volume to tissue volume ratio in the rats of the hindlimb-unloading treatment group were remarkably higher than those in the rats of the hindlimb-unloading control group (Figures 1A–1C). The trabecular number, trabecular thickness, trabecular spacing, and structure model index were also remarkably improved in the rats of the hindlimb-unloading treatment group (Figures 1D–1G).

Consistently, the results of the three-point bending test in the femur samples and compression analysis in the vertebra samples showed that the biomechanical properties such as maximum load, stiffness, stress, and Young's modulus were decreased after mechanical unloading in the rats of the hindlimb-unloading control group. All parameters were significantly enhanced after Ex-4 treatment (Figures 1H–1K). Thus, Ex-4 administration can prevent the bone loss and architectural deterioration caused by mechanical unloading in rats.

Ex-4 Stimulated Bone Formation and Increased the Number of Osteoblasts

To further assess how Ex-4 ameliorated the unloading-induced bone loss, we examined the bone formation-related parameters by bone histomorphometry analysis. In agreement with the imaging studies, dynamic histomorphometric analysis of the femoral bone sections from the hindlimb-unloading control group revealed a significant decrease in the bone mineral apposition rate (MAR), bone mineralizing surface when expressed per bone surface (MS/BS), and bone formation rate per bone surface (BFR/BS), determined by double calcine labeling, compared with the normal control group. However, MAR, BFR/BS, and MS/BS were significantly increased after Ex-4 treatment (Figures 2A–2D). In addition, osteocalcin, bone alkaline phosphatase, and N-terminal propeptide concentrations, biomarkers of bone formation in serum, were significantly reduced in the rats of the hindlimb-unloading control group compared with the normal control rats. The concentrations of the above biomarkers were significantly increased in the rats of the hindlimb-unloading treatment group compared with the hindlimb-unloading control group (Figures 2E–2G). Moreover, consistent with the reduction of bone formation markers, the number of osteoblasts, as well as the dynamic measures of bone formation, was reduced in the trabecular bone of the hindlimb-unloading control group, while Ex-4 remarkably increased the number of osteoblasts (Figures 2H and 2I). Interestingly, we also found that the number of adipocytes in the bone marrow of the hindlimb-unloading control group was increased compared with the normal control rats, while this number was dramatically decreased after Ex-4 treatment compared with the hindlimb-unloading control group (Figures 2J and 2K).
Ex-4 Promoted Osteoblasts and Suppressed BMSC Adipocyte Differentiation

Although our study indicated that Ex-4 exhibited a bone anabolic effect, there are no reports attesting the presence of GLP-1Rs in osteoblasts. Thus, GLP-1 cannot exert a direct effect on osteoblast differentiation. In addition, since GLP-1R is expressed in human BMSCs, in our attempt to investigate the mechanisms underlying GLP-1R-mediated bone anabolic effect we evaluated whether rat BMSCs expressed GLP-1R using real-time PCR, western blotting, and immunocytochemistry. Our results showed that GLP-1R was not expressed in primary osteoblasts cultured in osteogenesis induction medium (OIM) for 4 weeks, but was expressed in both rat insulinoma cell line (INS-1, GLP-1R-positive cell) and rat BMSCs (Figures 2L–2N). To evaluate the potential of BMSCs to differentiate into mature matrix-producing osteoblasts after Ex-4 treatment, we cultured BMSCs in OIM or in adipogenesis induction medium (AIM). Our results showed that Ex-4 significantly increased the expression of osteoblast differentiation-related genes and proteins, such as *Runx2*/*RUNX2* at day 7 after Ex-4 treatment, *Sp7/osterix* at day 10 (Figures 3A, 3B, 3D, and 3E), and impaired mineral deposition of cells at day 28 (Figures 3J and 3L). Ex-4 also increased the expression of mature matrix-producing osteoblast marker genes such as *Balp* and *Bglap* by real-time PCR at day 14 or day 28 after Ex-4 treatment, respectively (Figures 3G and 3H). In contrast, Ex-4 led to decreases in the mRNA and protein expression of the peroxisome proliferator-activated receptor γ (PPARγ) at day 3 (Figures 3C and 3F), as well as decreases in the lipoprotein lipase mRNA (*Lpl*) expression at day 14, and consequent lipid production in the differentiated adipocytes, as shown by oil red O at day 21 (Figures 3I, 3K, and 3M). These data suggested that Ex-4 played an important role in stimulating BMSCs osteoblast differentiation and inhibiting their differentiation into adipocytes. Furthermore, the GLP-1R antagonist exendin(9–39) [Ex(9–39)] attenuated the Ex-4 effect of improving osteogenesis and inhibiting adipogenesis of BMSCs (Figures 3A–3M), indicating that GLP-1R might play an important role in regulating BMSC differentiation. To further determine whether Ex-4 mediated BMSC differentiation through the activation of GLP-1Rs, we downregulated BMSC GLP-1R via lentiviral small hairpin RNA (shRNA) infection, and the cells were subsequently treated with...
Our results showed that the effect of Ex-4 on enhancing the expression of Runx2, Pparγ, Balp, and lpl was abolished when BMSCs were infected with shRNA15015, shRNA15016, or shRNA15017 (Figure S1). Moreover, GLP-1R downregulation by shRNA15016 reduced the effect of Ex-4 on the promotion of genes and protein expression related to osteoblast differentiation, and abolished Ex-4-promoted mineralization of differentiated osteoblasts. In contrast, the inhibitory effects of Ex-4 on adipocyte differentiation were reversed by GLP-1R downregulation (Figures 3A–3M). These data indicated that GLP-1R receptor was involved in BMSC osteoblast differentiation while it inhibited their differentiation into adipocytes.

**Ex-4 Effect on β-Catenin in BMSCs**

Since the canonical Wnt/β-catenin signaling pathway plays a pivotal role in the modulation of BMSC differentiation, we investigated whether it was involved in the effect of Ex-4 on BMSC differentiation through GLP-1R. Our western blot results showed that Ex-4 treatment increased the accumulation of β-catenin in the cytoplasm.
and enhanced the translocation of β-catenin in the nucleus in a time-dependent manner (Figures 4A–4C). These data were confirmed by immunofluorescence staining (Figure S2). Since the stable cytosolic β-catenin possesses the ability to transfer into the nucleus and bind with the transcription factor 7-like 2 (TCF7L2) to activate the expression of Wnt signaling target genes, including osteogenic regulatory genes, we evaluated the TCF7L2 mRNA expression level. Ex-4 upregulated TCF7L2 mRNA expression compared with control (Figure 4D). The block or downregulation of GLP-1R by Ex(9–39) or shRNA, respectively, inhibited the induction of TCF7L2 induced by Ex-4 (Figure 4D). In addition, the levels of the osteogenic regulators Runx2 and osterix were increased by Ex-4, but were decreased when BMSCs were pretreated with Ex(9–39) or shRNA-GLP-1R (Figures 3D and 3E). These results suggested that GLP-1R induced β-catenin nuclear translocation, and improved the expression of TCF7L2 and osteogenic regulators.

**Ex-4 Stimulated β-Catenin Nuclear Translocation through PKA/β-Catenin and PKA/PI3K/ AKT/GSK3β Signaling Pathways**

To further elucidate how GLP-1R interacted with the canonical Wnt/β-catenin signaling pathway, we investigated the downstream effectors used by GLP-1R and the Wnt/β-catenin system in BMSCs. Our results showed that the activation of GLP-1R by Ex-4 significantly enhanced the level of the PKA catalytic subunit (PKAc), which is associated with the increased phosphorylation of Ser-675 in the
Cytosolic β-catenin and accumulation of β-catenin in the nucleus. Forskolin treatment potentiated the PAKc and β-catenin level, either in the cytoplasm or in the nucleus, evoked by Ex-4 (Figures 5A–5D). Moreover, Ex-4-stimulated Ser675 phosphorylation and β-catenin nuclear accumulation were inhibited by either the GLP-1R antagonist Ex(9–39), the PKA inhibitor H89, or the shRNA-GLP-1R (Figures 5A–5D). Furthermore, the co-immunoprecipitation assay revealed that Ex-4 promoted the physical interaction between PKA and β-catenin (Figure 5E). We further explored the direct interaction between GLP-1R/PKA signaling and the phosphoinositide 3-kinase (PI3K)/AKT/β-catenin signaling pathway. Our results showed that the increase in PKAc induced by Ex-4 was associated with the phosphorylation of PI3K and its downstream target AKT, as well as with a decrease of phospho-glycogen synthase kinase 3β (p-GSK3β) (Ser9) and an increase of β-catenin accumulation in the cytoplasm and nucleus (Figures 5F–5L). Treatment with wortmannin, a PI3K inhibitor, inhibited the Ex-4-induced increases of pPI3K and p-AKT, increased the level of p-GSK3β, and abrogated the cytoplasmic and nuclear accumulation of β-catenin (Figures 5F and 5H–5L). However, wortmannin did not significantly suppress PKAc (Figure 5G). We next verified the association between PKA and PI3K through a co-immunoprecipitation assay in BMSCs using anti-PKA phosphosubstrate antibody followed by immunoblotting for PI3K. As shown in Figure 5M, PKA decreased PI3K in Ex-4-treated cells, indicating that Ex-4 facilitated the physical interaction between PKA and PI3K. In addition, Wnt3a, a prototypic Wnt ligand of the frizzled receptor, only increased the nuclear accumulation of β-catenin, but did not affect PKAc in BMSCs compared with the effects of Ex-4 on the induction of PKA and β-catenin. Moreover, Ex-4 stimulation of β-catenin nuclear accumulation was potentiated by the addition of Wnt3a (Figures 5N–5P). In contrast, Dickkopf 1 (DKK1), a Wnt signaling pathway inhibitor, did not inhibit the accumulation of β-catenin in the nucleus evoked by Ex-4 (Figures 5N and 5P). The knockdown of β-catenin by shRNA in BMSCs abolished Ex-4 stimulation of β-catenin accumulation in the nucleus of BMSCs, but did not affect Ex-4-induced PKA induction (Figures 5N–5P).

**β-Catenin Regulated BMSC Differentiation through GLP-1R**

To further confirm the key role of β-catenin in the modulating effect of GLP-1R on BMSC differentiation, we also explored the effect of silencing β-catenin in BMSCs. Our results showed that the effect of Ex-4 on Runx2, Ppary, Balp, and lpl expression was abolished when BMSCs were infected with shRNA19538 and shRNA19539, but not with shRNA19537 (Figure S3). Moreover, shRNA19538-mediated downregulation of β-catenin in BMSCs inhibited the

Figure 4. GLP-1R Activation Induced β-catenin Nuclear Translocation in BMSCs

(A) Western blot of cytoplasmic (C-β-cat) and nuclear β-catenin (N-β-cat) proteins in BMSCs stimulated by 10 nM Ex-4 at the indicated times.

(B and C) Bars represent the quantification of the cytoplasmic and nuclear β-catenin protein normalized by β-actin or histone H3.1.

(D) Real-time PCR of TCF7L2 mRNA in BMSCs subjected to different treatments. BMSCs were cultured in OIM.

Data are expressed as mean ± SD from three independent experiments. **p < 0.01 versus vehicle treatment (Con), ##p < 0.01 versus Ex-4 treatment by one-way ANOVA followed by a Student-Newman-Keuls t test.

584 Stem Cell Reports | Vol. 6 | 579–591 | April 12, 2016 | ©2016 The Authors
Figure 5. GLP-1R Activation Stimulated Wnt/β-Catenin Signaling in BMSCs

(A–D) Western blot of catalytic PKA (PKAc), phosphorylated β-catenin (β-cat Ser675), and nuclear β-catenin (N-β-cat) proteins in BMSCs under different treatments. In (B)–(D) bars represent the quantification of catalytic PKA, β-cat Ser675, and nuclear β-catenin protein normalized by β-actin or histone H3.1.

(E) Immunoprecipitation and western blot of the interaction between PKA and β-catenin in BMSCs cytoplasm after Ex-4 treatment.

(F) Western blot of PKAc, phospho-PI3K (p-PI3K), phospho-AKT (p-AKT), phospho-GSK3β (p-GSK3β), C-β-cat, or N-β-cat proteins in BMSCs after treatment with Ex-4 or Ex-4 plus wortmannin (PI3K inhibitor).

(legend continued on next page)
expression of osteoblast differentiation and maturation markers such as Runx2/RUNX2, Sp7/osterix, Balp, and Bglap, and significantly reduced the mineralization evoked by Ex-4 (Figures 6A, 6B, 6D, 6E, 6G, 6H, 6J, and 6L). On the other hand, the inhibition of the adipocyte differentiation and lipid production in BMSCs mediated by Ex-4 was reversed by β-catenin downregulation (Figures 6C, 6F, 6I, 6K, and 6M). All the Ex-4-induced functions on BMSCs, such as induction of the markers related to osteoblast differentiation, BMSC mineralization, and the repression of the markers related to adipocyte differentiation, were not affected by DKK1 treatment (Figure 6), suggesting that DKK1 did not affect Ex-4-mediated increase of nuclear β-catenin via the GLP-1R/PKA pathway.

DISCUSSION

The present study analyzed and described the link between GLP-1R and the Wnt/β-catenin signaling pathway in BMSCs, in which GLP-1R receptor crosstalks with the canonical Wnt/β-catenin pathway to promote bone formation. Our results demonstrated that GLP-1R, mainly expressed on BMSCs, promoted BMSC osteoblast differentiation and inhibited their differentiation into adipocytes, leading to the anabolic bone formation and amelioration of osteoporosis in hindlimb-unloading rats. The mechanisms of GLP-1R-mediated osteogenic action is exerted by a dual role: through the cAMP/PKA/β-catenin/T cell factor (TCF) pathway to initiate osteoblast differentiation, and through the PKA/PI3K/Akt/GSK3β pathway to inhibit β-catenin degradation and promote its nuclear accumulation in BMSCs, which thereafter resulted in the anabolic bone formation.

The gut-derived hormones, such as serotonin, peptide YY (PYY), and incretins, are now recognized as critical regulators in bone homeostasis (Dicembrini et al., 2012; Wong et al., 2012; Yadav et al., 2008), since they display a negative relationship with osteoblast activity. Therefore, these results provide evidence that the inhibition of the biosynthesis of gut-derived serotonin and PYY could become an effective method to treat low-bone-mass diseases such as osteoporosis.

In contrast to the negative regulation of serotonin and PYY on bone homeostasis, our study demonstrated that GLP-1R displayed a positive correlation with osteoblast activity and bone growth. The treatment with the GLP-1R agonist Ex-4 resulted in a significant increase in bone mass in the hindlimb-unloading rats, associated with the increase in osteoblast number and serum level of bone formation biomarkers, with a parallel decrease in the adipocyte number. In addition, the treatment with Ex-4 lowered the increased rates of bone resorption biomarkers (Figure S4). These findings strongly indicated that Ex-4 prevented osteopenia by promoting bone formation and suppressing bone resorption. The effect of Ex-4 in the control of bone resorption is exerted through a calcitomin-dependent pathway (Yamada et al., 2008). However, GLP-1Rs are not present in osteoblasts, so GLP-1 cannot exert a direct effect on them (Bollag et al., 2000; Yamada et al., 2008). Therefore, the anabolic effects of Ex-4 on bone formation that we observed were not a consequence of a direct action on osteoblasts. As it is well known that osteoblasts and adipocytes both differentiate from common mesenchymal precursor cells (Park et al., 2012), we speculated that the changes in the osteoblast and adipocyte numbers might be due to BMSC differentiation preferably to adipocytes rather than osteoblasts, leading to bone formation reduction and consequent osteopenia development, while GLP-1R is expressed in human BMSCs to promote cellular proliferation and prevent the differentiation of human MSCs into adipocytes (Sanz et al., 2010). Thus, we hypothesized that BMSC GLP-1R might play a regulatory role in cell fate, resulting in osteoblast differentiation rather than adipocyte differentiation. To test this hypothesis, we investigated the roles of GLP-1R on BMSC differentiation. BMSC GLP-1R activation by Ex-4 significantly enhanced the expression of osteoblastogenic biomarkers, thus promoting osteoblastic mineralization, and inhibited the induction of adipocyte differentiation biomarkers, thus decreasing endogenous lipid deposits in cells. GLP-1R silencing or block through its antagonists reduced the effects described above. Taken together, these results suggested that GLP-1R is involved in BMSC differentiation into osteoblasts.

Recent studies indicate that the canonical Wnt pathway affects BMSC osteogenic differentiation. Wnt signaling can promote osteoblastic precursor differentiation into more differentiated osteoblasts and can serve as a negative regulator of adipogenesis (Glass et al., 2005; Krishnan et al., 2006). This differentiation process is tightly regulated by complex signaling events (Luu et al., 2007). β-Catenin is
Figure 6. β-Catenin Silencing Abolished Ex-4 Regulatory Effects on BMSC Differentiation

(A–C) Real-time PCR of Runx2, Sp7, and Pparγ mRNA in BMSCs subjected to different treatments. Runx2 and Sp7 mRNA expression in BMSCs cultured in OIM were examined at days 7 and 10 after treatment, respectively. Pparγ mRNA expression in BMSCs cultured in AIM was examined at day 3 after treatment.

(D–F) Western blot of RUNX2, osterix, and PPARγ proteins in BMSCs subjected to different treatments. RUNX2 and osterix protein expression in BMSCs cultured in OIM were examined at days 7 and 10 after treatment, respectively. PPARγ protein expression in BMSCs cultured in AIM was examined at day 3 after treatment. Bars represent the protein quantitative data normalized by β-actin.

(G–I) Real-time PCR of Balp, Bglap, and Lpl mRNA in BMSCs subjected to different treatments. Balp and Bglap mRNA expression in BMSCs cultured in OIM were examined at days 14 and 28 after treatment, respectively. Lpl mRNA expression in BMSCs cultured in AIM was examined at day 14 after treatment.

(legend continued on next page)
GLP-1R is localized in multiple tissues and cell types (Holst, 2007). GLP-1 agonist binding to GLP-1R activates various different pathways involved in the proliferation, differentiation, and protection from apoptosis. On the basis of our present results we concluded that PKA, a GLP-1R downstream effector exerting a strong bond to β-catenin and PI3K and induced by Ex-4, played a dual role in its interaction with the Wnt/β-catenin signaling pathway. First, at the molecular level, PKA phosphorylated β-catenin at its Ser675 and promoted β-catenin nuclear translocation, and subsequently recruited LEF/TCF DNA binding factors to initiate the expression of osteoblast differentiation-related gene, driving BMSC differentiation into osteoblasts. It has also been reported that PKA phosphorylates β-catenin at two sites, Ser552 and Ser675, thus preventing its ubiquitination and thereby stabilizing β-catenin (Hino et al., 2005; Taurin et al., 2006). Second, PKA also phosphorylated PI3K, which in turn phosphorylated AKT, leading to GSK3β phosphorylation. GSK3β is a key enzyme that negatively regulates the canonical Wnt/β-catenin signaling pathway, and canonical Wnt signaling activation also requires the inhibition of GSK3β activity (Clevers and Nusse, 2012). The PKA signaling pathway can crosstalk with the PI3K/AKT pathway in endothelial cells (Namkoong et al., 2009), and the PI3K/AKT pathway can communicate with the GSK3β/β-catenin pathway in epithelial cells (Son et al., 2012). Phosphorylated GSK3β dephosphorylates β-catenin and prevents its degradation in the ubiquitin-dependent proteosome pathway. This event also helps to promote β-catenin translocation into the nucleus, leading to BMSC osteoblast differentiation. In summary, our results indicated that BMSC GLP-1R plays a crucial role in the regulation of osteoblast differentiation by interacting with the PKA/β-catenin and PKA/PI3K/AKT/GSK3β/β-catenin signaling pathways, both representing critical events in Ex-4-induced anabolic bone formation (Figure 7).

### Cell Experiments

BMSCs were isolated from the femurs and tibias of 2- to 3-week-old Sprague-Dawley male rats (Animal Center of Fourth Military Medical University). The BMSCs derived from the second to the fourth passages were used in all the experiments, at least three different batches per experiment were used, and each experiment was performed in triplicate. BMSC differentiation was performed using osteogenic or adipogenic induction medium in all experiments. The BMSCs were cultured in OIM containing minimal essential medium α (α-MEM), 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mg/l ascorbic acid (Sigma-Aldrich), 10 mM dexamethasone (Sigma-Aldrich), and 10 mM β-glycerophosphate (Sigma-Aldrich) to induce osteogenic differentiation, while they were cultured in AIM containing α-MEM, 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 5 μg/ml insulin (Sigma-Aldrich), 1 μM dexamethasone (Sigma-Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich), and 100 μM indomethacin (Sigma-Aldrich) to induce adipogenic differentiation. BMSC GLP-1R and β-catenin were knocked down by lentivirus transduction encoding shRNA. The osteogenic potential was confirmed by mineralization assay and the adipogenic potential was confirmed through oil red O staining. Quantitative

### EXPERIMENTAL PROCEDURES

#### Animal Experiments

All experiments and animal care procedures were performed in accordance with the recommendations and guidelines of the NIH and were approved by the Animal Care and Use Committee of the Fourth Military Medical University (X’ian, China). The rat tail suspension was performed for 28 days as previously described (Morey-Holton and Globus, 2002). Ex-4 (GL Biochem), 4.2 μg/kg/day, was intraperitoneally administered to the rats of the hindlimb-unloading treatment group for 28 days, while the rats belonging to the hindlimb-unloading control group received an intraperitoneal injection of the same amount of normal saline for the same number of days. The Ex-4 dose used was chosen according to our previous experiment (Ma et al., 2013). Femurs and lumbar vertebrae (L3–L4) were removed and stored at –80°C for microCT analysis and biomechanical testing. The femurs and vertebrae were subjected to a three-point bending test and axial compression analysis using a servo-hydraulic materials testing machine (MTS 858 Mini Bionix II; MTS Systems) to perform a biomechanical analysis. Serum bone formation markers were measured by commercially available ELISA kits. Bone static histomorphometry measurements and bone histology of the trabecular bone were performed as described in Supplemental Experimental Procedures.

#### (J and L) Mineralized matrix visualized in BMSCs and its quantification. BMSCs were cultured in OIM and stained with alizarin red S at day 28 after treatment. Scale bar, 3 mm.

#### (K and M) Lipid accumulation in BMSCs and its quantification. BMSCs were cultured in AIM and stained with oil red O at day 21 after treatment. Scale bar, 50 μm.

BMSCs were treated with vehicle (Con), 10 nM Ex-4 alone (Ex-4), 10 nM Ex-4 plus 0.5 mg/ml DKK1 (Ex-4+DKK1); β-catenin silenced BMSCs by sh-β-catenin were treated with 10 nM Ex-4 alone (Ex-4+sh-β-cat) in OIM or AIM. Data are expressed as mean ± SD from three independent experiments. **p < 0.01 versus vehicle treatment (Con) and #p < 0.01 versus Ex-4 treatment by one-way ANOVA followed by a Student-Newman-Keuls t test.

588 Stem Cell Reports | Vol. 6 | 579–591 | April 12, 2016 | ©2016 The Authors
real-time PCR, western blot analysis, co-immunoprecipitation, and confocal microscopy detection were also performed (see Supplemental Experimental Procedures).

**Statistical Analysis**

Data were expressed as mean ± SD and analyzed using SPSS for Windows version 15.0. Statistical significance was determined by one-way ANOVA followed by post hoc multiple comparisons using a Student-Newman-Keuls t test. A value of p < 0.05 was considered statistically significant.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, seven figures and one table and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2016.02.002.

**AUTHOR CONTRIBUTIONS**

All authors extensively contributed to the work described in this paper. X.x.L. designed and supervised the entire study. J.r.M., X.M., and N.W. performed the experiments and analyzed the data. M.J., H.n.Z., and Z.H. collected and assembled the data. L.B., M.k.L., and Z.b.Y. analyzed and interpreted the data. L.B., Y.y.W., and X.y.X. performed the tissue section and the staining. X.M., N.W., and Y.Z. performed the cell culture. X.x.L., G.h.H., and J.r.M. wrote the manuscript.

**ACKNOWLEDGMENTS**

This research was supported by the grants from the National Natural Science Foundation of China (Nos. 81201515, 81471093, 81402931, and 81460560) and Natural Science Foundation of Shaanxi Province (Nos. 2013JQ4027 and 2015JM8421).

Received: August 24, 2015
Revised: January 30, 2016
Accepted: February 1, 2016
Published: March 3, 2016

**REFERENCES**

Aoyama, E., Watari, I., Podyma-Inoue, K.A., Yanagishita, M., and Ono, T. (2014). Expression of glucagon-like peptide-1 receptor
and glucose-dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells. Int. J. Mol. Med. 34, 475–482.

Armbrecht, G., Belavy, D.L., Backstrom, M., Beller, G., Alexandre, C., Rizzoli, R., and Felsenberg, D. (2011). Trabecular and cortical bone density and architecture in women after 60 days of bed rest using high-resolution pQCT: WISE 2005. J. Bone Miner Res. 26, 2399–2410.

Bollag, R.J., Zhong, Q., Phillips, P., Min, L., Zhong, L., Cameron, R., Mulloy, A.L., Rasmussen, H., Qin, F., Ding, K.H., and Isales, C.M. (2000). Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 141, 1228–1235.

Clevers, H., and Nusse, R. (2012). Wnt/beta-catenin signaling and disease. Cell 149, 1192–1205.

D’Alimonte, I., Lannutti, A., Pipino, C., Di Tomo, P., Pierdomenico, L., Cianci, E., Antonucci, I., Marchisio, M., Romano, M., Stuppia, L., et al. (2013). Wnt signaling behaves as a “master regulator” in the osteogenic and adipogenic commitment of human amniotic fluid mesenchymal stem cells. Stem Cell Rev. 9, 642–654.

Dicembrini, I., Mannucci, E., and Rotella, C.M. (2012). Bone: incretin hormones perceive or receiver? Exp. Diabetes Res. 2012, 519784.

Edwards, M.H., Dennison, E.M., Aihie Sayer, A., Fielding, R., and Cooper, C. (2015). Osteoporosis and sarcopenia in older age. Bone 80, 126–130.

Glass, D.A., 2nd, Bialek, P., Ahn, J.D., Starbuck, M., Patel, M.S., Clevers, H., Takei, M.M., Long, F., McMahon, A.P., Lang, R.A., et al. (2005). Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8, 751–764.

Hayes, M.R., Leichner, T.M., Zhao, S., Lee, G.S., Chowansky, A., Zimmer, D., De Jonghe, B.C., Kosanis, S.E., Grill, H.J., and Bence, K.K. (2011). Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab. 13, 320–330.

Hino, S., Tanji, C., Nakayama, K.I., and Kikuchi, A. (2005). Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol. Cell Biol. 25, 9063–9072.

Holst, J.J. (2007). The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409–1439.

Jeon, Y.K., Bae, M.J., Kim, J.I., Kim, J.H., Choi, S.J., Kwon, S.K., An, J.H., Kim, S.S., Kim, B.H., Kim, Y.K., et al. (2014). Expression of glucagon-like peptide 1 receptor during osteogenic differentiation of adipose-derived stem cells. Endocrinol. Metab. (Seoul) 29, 567–573.

Jiang, L., Xu, L., Song, Y., Li, J., Mao, J., Zhao, A.Z., He, W., Yang, J., and Dai, C. (2013). Calmodulin-dependent protein kinase II/CAMP response element-binding protein/Wnt/beta-catenin signaling cascade regulates angiotensin II-induced podocyte injury and albuminuria. J. Biol. Chem. 288, 23368–23379.

Ke, J., Zhang, C., Harikumar, K.G., Zylstra-Diegel, C.R., Wang, L., Mowry, L.E., Miller, L.J., Williams, B.O., and Xu, H.E. (2012). Modulation of beta-catenin signaling by glucagon receptor activation. PLoS One 7, e33676.

Kim, J.Y., Lee, S.K., Jo, K.J., Song, D.Y., Lim, D.M., Park, K.Y., Bonewald, L.F., and Kim, B.J. (2013). Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci. 92, 533–540.

Kondo, H., Ezura, Y., Nakamoto, T., Hayata, T., Notomi, T., Sorima, H., Takeda, S., and Noda, M. (2011). MURF1 deficiency suppresses unloading-induced effects on osteoblasts and osteoclasts to lead to bone loss. J. Cell Biochem. 112, 3525–3530.

Krishnan, V., Bryant, H.U., and Macdougald, O.A. (2006). Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116, 1202–1209.

Lau, R.Y., and Guo, X. (2011). A review on current osteoporosis research: with special focus on disuse bone loss. J. Osteoporos. 2011, 293808.

Liu, Z., and Habener, J.F. (2008). Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J. Biol. Chem. 283, 8723–8735.

Liu, G., Vijayakumar, S., Grumolato, L., Arroyave, R., Qiao, H., Akiri, G., and Aaronson, S.A. (2009). Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells. J. Cell Biol. 185, 67–75.

Luu, H.H., Song, W.X., Luo, X., Manning, D., Luo, J., Deng, Z.L., Sharff, K.A., Montag, A.G., Haydon, R.C., and He, T.C. (2007). Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J. Orthop. Res. 25, 665–677.

Ma, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., and Luo, X. (2013). Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariecetomized rats. J. Bone Miner Res. 28, 1641–1652.

Morey-Holton, E.R., and Globus, R.K. (2002). Hindlimb unloading rodent model: technical aspects. J. Appl. Physiol. (1985) 92, 1367–1377.

Nakamura, H., Aoki, K., Masuda, W., Alles, N., Nagano, K., Fukushima, H., Osawa, K., Yasuda, H., Nakamura, I., Mikuni-Takagaki, Y., et al. (2013). Disruption of NF-kappaB1 prevents bone loss caused by mechanical unloading. J. Bone Miner Res. 28, 1457–1467.

Namkoong, S., Kim, C.K., Cho, Y.L., Kim, J.H., Lee, H., Ha, K.S., Choe, J., Kim, P.H., Won, M.H., Kwon, Y.G., et al. (2009). Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling. Cell Signal. 21, 906–915.

Pacheco-Pantoja, E.L., Ranganath, L.R., Gallagher, J.A., Wilson, P.J., and Fraser, W.D. (2011). Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol. 11, 12.

Park, D., Spencer, J.A., Koh, B.I., Kobayashi, T., Fujisaki, J., Clemens, T.L., Lin, C.P., Kronenberg, H.M., and Scadden, D.T. (2012). Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell 10, 259–272.

Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S., and Marshak, D.R. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284, 143–147.
Rachner, T.D., Khosla, S., and Hofbauer, L.C. (2011). Osteoporosis: now and the future. Lancet 377, 1276–1287.

Sanz, C., Vazquez, P., Blazquez, C., Barrio, P.A., Alvarez Mdel, M., and Blazquez, E. (2010). Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am. J. Physiol. Endocrinol. Metab. 298, E634–E643.

Shui, C., Spelsberg, T.C., Riggs, B.L., and Khosla, S. (2003). Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J. Bone Miner Res. 18, 213–221.

Son, Y.O., Wang, L., Poyil, P., Budhraja, A., Hitron, J.A., Zhang, Z., Lee, J.C., and Shi, X. (2012). Cadmium induces carcinogenesis in BEAS-2B cells through ROS-dependent activation of PI3K/AKT/GSK-3beta/beta-catenin signaling. Toxicol. Appl. Pharmacol. 264, 153–160.

Taurin, S., Sandbo, N., Qin, Y., Browning, D., and Dulin, N.O. (2006). Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J. Biol. Chem. 281, 9971–9976.

Wong, I.P., Driessler, F., Khor, E.C., Shi, Y.C., Horner, B., Nguyen, A.D., Enriquez, R.E., Eisman, J.A., Sainsbury, A., Herzog, H., et al. (2012). Peptide YY regulates bone remodeling in mice: a link between gut and skeletal biology. PLoS One 7, e40038.

Yadav, V.K., Ryu, J.H., Suda, N., Tanaka, K.F., Gingrich, J.A., Schutz, G., Glorieux, F.H., Chiang, C.Y., Zajac, J.D., Insogna, K.L., et al. (2008). Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135, 825–837.

Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D.J., Seino, Y., and Inagaki, N. (2008). The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149, 574–579.

Yang, Y.Q., Tan, Y.Y., Wong, R., Wenden, A., Zhang, L.K., and Rabie, A.B. (2012). The role of vascular endothelial growth factor in ossification. Int. J. Oral Sci. 4, 64–68.

Zhang, M., Mahoney, E., Zuo, T., Manchanda, P.K., Davuluri, R.V., and Kirschner, L.S. (2014). Protein kinase A activation enhances beta-catenin transcriptional activity through nuclear localization to PML bodies. PLoS One 9, e109523.